image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - US
$ 8.26
-0.602 %
$ 3.77 B
Market Cap
-9.49
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one AMRX stock under the worst case scenario is HIDDEN Compared to the current market price of 8.26 USD, Amneal Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one AMRX stock under the base case scenario is HIDDEN Compared to the current market price of 8.26 USD, Amneal Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one AMRX stock under the best case scenario is HIDDEN Compared to the current market price of 8.26 USD, Amneal Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
2.39 B REVENUE
8.20%
204 M OPERATING INCOME
-1.01%
-48.7 M NET INCOME
80.88%
346 M OPERATING CASH FLOW
430.84%
-69.2 M INVESTING CASH FLOW
60.31%
-213 M FINANCING CASH FLOW
-99.37%
702 M REVENUE
0.10%
88.8 M OPERATING INCOME
-6.98%
11.8 M NET INCOME
-29.96%
142 M OPERATING CASH FLOW
257.50%
-20.7 M INVESTING CASH FLOW
-220.37%
-92.3 M FINANCING CASH FLOW
-163.20%
Balance Sheet Amneal Pharmaceuticals, Inc.
image
Current Assets 1.38 B
Cash & Short-Term Investments 91.5 M
Receivables 614 M
Other Current Assets 673 M
Non-Current Assets 2.09 B
Long-Term Investments 37.1 M
PP&E 550 M
Other Non-Current Assets 1.51 B
Current Liabilities 847 M
Accounts Payable 144 M
Short-Term Debt 228 M
Other Current Liabilities 475 M
Non-Current Liabilities 2.61 B
Long-Term Debt 2.52 B
Other Non-Current Liabilities 83.1 M
EFFICIENCY
Earnings Waterfall Amneal Pharmaceuticals, Inc.
image
Revenue 2.39 B
Cost Of Revenue 1.57 B
Gross Profit 821 M
Operating Expenses 616 M
Operating Income 204 M
Other Expenses 253 M
Net Income -48.7 M
RATIOS
34.28% GROSS MARGIN
34.28%
8.54% OPERATING MARGIN
8.54%
-3.51% NET MARGIN
-3.51%
-424.61% ROE
-424.61%
-2.42% ROA
-2.42%
9.29% ROIC
9.29%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Amneal Pharmaceuticals, Inc.
image
Net Income -48.7 M
Depreciation & Amortization 229 M
Capital Expenditures -69.2 M
Stock-Based Compensation 26.8 M
Change in Working Capital -47.2 M
Others 232 M
Free Cash Flow 276 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Amneal Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for AMRX of $10 , with forecasts ranging from a low of $8 to a high of $12 .
AMRX Lowest Price Target Wall Street Target
8 USD -3.15%
AMRX Average Price Target Wall Street Target
10 USD 21.07%
AMRX Highest Price Target Wall Street Target
12 USD 45.28%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Amneal Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
1.11 M USD 4
3-6 MONTHS
1.27 M USD 2
6-9 MONTHS
256 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 weeks ago
Jan 02, 2025
Sell 139 K USD
Patel Gautam
Director
- 17410
8.01 USD
1 month ago
Nov 22, 2024
Sell 143 K USD
Kiely John
Director
- 17058
8.38 USD
1 month ago
Nov 21, 2024
Sell 56.9 K USD
Autor Deborah M.
Director
- 6771
8.41 USD
1 month ago
Nov 22, 2024
Sell 277 K USD
Autor Deborah M.
Director
- 33229
8.34 USD
1 month ago
Nov 21, 2024
Sell 115 K USD
Daly Jason B.
SVP, Chief Legal Officer
- 13665
8.4 USD
2 months ago
Nov 15, 2024
Sell 376 K USD
Daly Jason B.
SVP, Chief Legal Officer
- 43657
8.61 USD
5 months ago
Aug 14, 2024
Sell 176 K USD
BOYER ANDREW S
Executive Vice President
- 22486
7.81 USD
5 months ago
Aug 15, 2024
Sell 316 K USD
BOYER ANDREW S
Executive Vice President
- 40225
7.85 USD
5 months ago
Aug 14, 2024
Sell 775 K USD
Shah Nikita
Executive Vice President
- 100000
7.75 USD
8 months ago
May 16, 2024
Sell 98.4 K USD
Autor Deborah M.
Director
- 14553
6.76 USD
8 months ago
May 17, 2024
Sell 158 K USD
Autor Deborah M.
Director
- 23447
6.727 USD
1 year ago
Aug 11, 2023
Sell 121 K USD
BOYER ANDREW S
Executive Vice President
- 29302
4.1267 USD
2 years ago
Dec 12, 2022
Sell 9.1 M USD
TPG GP A, LLC
Director
- 3884600
2.3414 USD
3 years ago
Dec 17, 2021
Bought 210 K USD
Patel Gautam
Director
+ 50000
4.21 USD
3 years ago
Dec 15, 2021
Sell 7.9 K USD
Shah Nikita
Executive Vice President
- 2000
3.95 USD
3 years ago
Mar 15, 2021
Sell 249 K USD
Shah Nikita
Executive Vice President
- 36330
6.8673 USD
4 years ago
May 19, 2020
Bought 44 K USD
Kiely John
Director
+ 10000
4.4 USD
4 years ago
May 15, 2020
Bought 99 K USD
George Jeffrey P.
Director
+ 23810
4.16 USD
4 years ago
Mar 18, 2020
Bought 553 K USD
MEISTER PAUL M
Director
+ 204210
2.71 USD
4 years ago
Mar 17, 2020
Bought 417 K USD
MEISTER PAUL M
Director
+ 149439
2.79 USD
4 years ago
Mar 03, 2020
Bought 464 K USD
Patel Gautam
director, 10 percent owner:
+ 117889
3.94 USD
4 years ago
Mar 02, 2020
Bought 125 K USD
Patel Gautam
director, 10 percent owner:
+ 32111
3.88 USD
5 years ago
Aug 28, 2019
Bought 120 K USD
Nark Ted C
Director
+ 50000
2.39 USD
5 years ago
Aug 16, 2019
Bought 72.3 K USD
Bhadauria Pradeep
SVP, Chief Scientific Officer
+ 30000
2.41 USD
5 years ago
Aug 07, 2019
Bought 193 K USD
BOYER ANDREW S
Exec VP, Comm Optns
+ 66666
2.89 USD
5 years ago
May 15, 2019
Bought 59.4 K USD
Bhadauria Pradeep
SVP, Chief Scientific Officer
+ 7000
8.48 USD
5 years ago
May 13, 2019
Bought 180 K USD
BOYER ANDREW S
Exec VP, Comm Optns
+ 19000
9.46 USD
5 years ago
Mar 12, 2019
Bought 203 K USD
BISARO PAUL
Executive Chairman
+ 17000
11.97 USD
5 years ago
Mar 06, 2019
Sell 289 K USD
TERRERI PETER R
Director
- 23345
12.39 USD
6 years ago
Aug 21, 2018
Sell 1.17 M USD
Shah Nikita
SVP, Chief HR Officer
- 50000
23.46 USD
6 years ago
Aug 21, 2018
Sell 277 K USD
Reasons Bryan M.
CFO
- 11698
23.65 USD
7. News
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist. businesswire.com - 1 month ago
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hit a 52 Week High, Can the Run Continue? Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 2 months ago
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President & Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President & Chief Financial Officer Joe Renda - Senior Vice President & Chief Commercial Officer, Specialty Conference Call Participants David Amsellem - Piper Sandler Balaji Prasad - Barclays Bank Leszek Sulewski - Truist Securities Chris Schott - JPMorgan Operator Hello, everyone and thank you for your patience. The Amneal Pharmaceuticals Third Quarter 2024 Earnings Call will begin shortly. seekingalpha.com - 2 months ago
Amneal (AMRX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 2 months ago
Amneal Pharmaceuticals (AMRX) Surpasses Q3 Earnings and Revenue Estimates Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.19 per share a year ago. zacks.com - 2 months ago
Amneal Reports Third Quarter 2024 Financial Results BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Reports Third Quarter 2024 Financial Results. businesswire.com - 2 months ago
Amneal (AMRX) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures Evaluate the expected performance of Amneal (AMRX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com - 2 months ago
5 Stocks Backed by High Efficiency for Solid Gains Amid Volatility Invest in stocks of AMRX, CRON, CSV, BFST and APH to tap their high-efficiency levels. zacks.com - 2 months ago
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 months ago
How to Find Great Cheap Stocks Under $10 to Buy in October On top of their cheap price tags, Wall Street analysts are high on all of these stocks and their improving earnings outlooks earn them strong Zacks Ranks. zacks.com - 3 months ago
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year? Here is how Amneal Pharmaceuticals (AMRX) and Astrazeneca (AZN) have performed compared to their sector so far this year. zacks.com - 3 months ago
Amneal to Report Third Quarter 2024 Results on November 8, 2024 BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report Third Quarter 2024 Results on November 8, 2024. businesswire.com - 3 months ago
8. Profile Summary

Amneal Pharmaceuticals, Inc. AMRX

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 3.77 B
Dividend Yield 0.00%
Description Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Contact 400 Crossing Boulevard, Bridgewater, NJ, 08807 https://www.amneal.com
IPO Date May 7, 2018
Employees 7850
Officers Mr. Chintu Patel R.Ph. Co-Founder, Co-Chief Executive Officer & Director Mr. Pranav Mehta Senior Vice President of Strategic Sourcing & Supply Management Ms. Nikita Shah Executive Vice President & Chief Human Resources Officer Mr. Chirag K. Patel Co-Founder, Co-Chief Executive Officer, President & Director Mr. Anthony DiMeo Head of Investor Relations Dr. Sanjay Kumar Jain Ph.D. Chief Quality Officer Mr. Jason B. Daly Esq. Senior Vice President, Chief Legal Officer & Corporate Secretary Mr. Andrew S. Boyer Executive Vice President & Chief Commercial Officer of Generics Mr. Gregory Sgammato Senior Vice President of Corporate Development Mr. Anastasios G. Konidaris Executive Vice President & Chief Financial Officer